Literature DB >> 14984391

Hallucination focused integrative treatment improves quality of life in schizophrenia patients.

D Wiersma1, J A Jenner, F J Nienhuis, G van de Willige.   

Abstract

OBJECTIVE: Psychosocial treatment seems to be effective in the management of schizophrenia, although less in the area of quality of life and social functioning. To study the effectiveness of a hallucination focused integrated treatment with cognitive-behaviour therapy and coping training among schizophrenia patients suffering from 'hearing voices'.
METHOD: In a randomized controlled trial (RCT) with 31 patients in the integrated treatment condition and 32 patients in the routine care condition, quality of life was assessed with the self-report questionnaire of the WHO (Bref), and social role functioning with an interviewer based schedule, at entry and 9 (post-treatment) and 18 months later.
RESULTS: Follow-up data suggest a significant improvement of quality of life and in particular in social role functioning (effect size 0.64) in favour of the integrated treatment.
CONCLUSION: The integrated treatment seems to be effective in reducing overall disability levels and number of patients with serious disabilities.

Entities:  

Mesh:

Year:  2004        PMID: 14984391     DOI: 10.1046/j.0001-690x.2003.00237.x

Source DB:  PubMed          Journal:  Acta Psychiatr Scand        ISSN: 0001-690X            Impact factor:   6.392


  14 in total

1.  Efficacy of psychological therapy in schizophrenia: conclusions from meta-analyses.

Authors:  Mario Pfammatter; Ulrich Martin Junghan; Hans Dieter Brenner
Journal:  Schizophr Bull       Date:  2006-08-11       Impact factor: 9.306

2.  Economic aspects of peer support groups for psychosis.

Authors:  A D Stant; S Castelein; R Bruggeman; J T van Busschbach; M van der Gaag; H Knegtering; D Wiersma
Journal:  Community Ment Health J       Date:  2009-03-24

3.  Changes in quality of life in chronic psychiatric patients: a comparison between EuroQol (EQ-5D) and WHOQoL.

Authors:  Gerard van de Willige; Durk Wiersma; Fokko J Nienhuis; Jack A Jenner
Journal:  Qual Life Res       Date:  2005-03       Impact factor: 4.147

4.  Social disinterest attitudes and group cognitive-behavioral social skills training for functional disability in schizophrenia.

Authors:  Eric Granholm; Dror Ben-Zeev; Peter C Link
Journal:  Schizophr Bull       Date:  2009-07-23       Impact factor: 9.306

Review 5.  Social skills programmes for schizophrenia.

Authors:  Muhammad Qutayba Almerie; Muhammad Okba Al Marhi; Muhammad Jawoosh; Mohamad Alsabbagh; Hosam E Matar; Nicola Maayan; Hanna Bergman
Journal:  Cochrane Database Syst Rev       Date:  2015-06-09

6.  The effects of cognitive therapy on hallucinations in patients with schizophrenia.

Authors:  Alanna Propst
Journal:  Mcgill J Med       Date:  2011-06

7.  Cognitive behavior therapy for schizophrenia: effect sizes, clinical models, and methodological rigor.

Authors:  Til Wykes; Craig Steel; Brian Everitt; Nicholas Tarrier
Journal:  Schizophr Bull       Date:  2007-10-25       Impact factor: 9.306

Review 8.  Current approaches to treatments for schizophrenia spectrum disorders, part II: psychosocial interventions and patient-focused perspectives in psychiatric care.

Authors:  Wai Tong Chien; Sau Fong Leung; Frederick Kk Yeung; Wai Kit Wong
Journal:  Neuropsychiatr Dis Treat       Date:  2013-09-25       Impact factor: 2.570

Review 9.  Psychological therapies for auditory hallucinations (voices): current status and key directions for future research.

Authors:  Neil Thomas; Mark Hayward; Emmanuelle Peters; Mark van der Gaag; Richard P Bentall; Jack Jenner; Clara Strauss; Iris E Sommer; Louise C Johns; Filippo Varese; José Manuel García-Montes; Flavie Waters; Guy Dodgson; Simon McCarthy-Jones
Journal:  Schizophr Bull       Date:  2014-07       Impact factor: 9.306

Review 10.  Psychiatric symptoms in glioma patients: from diagnosis to management.

Authors:  Florien W Boele; Alasdair G Rooney; Robin Grant; Martin Klein
Journal:  Neuropsychiatr Dis Treat       Date:  2015-06-10       Impact factor: 2.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.